10-K: Foghorn Therapeutics Inc. Files 10-K, Highlights Pipeline Progress and Strategic Collaboration

Foghorn Therapeutics Inc.'s 2023 10-K filing details its financial status, pipeline advancements, and strategic collaboration with Lilly, emphasizing its focus on chromatin regulatory system therapeutics.

Summary

• Foghorn Therapeutics Inc. is a clinical-stage biotechnology company focused on developing precision medicines by targeting the chromatin regulatory system.
• The company's proprietary Gene Traffic Control platform is used to identify and develop novel therapeutics.
• Foghorn has over 10 programs in development, including one clinical-stage drug candidate, FHD-286, currently in Phase 1 trials for relapsed and/or refractory acute myeloid leukemia (AML).
• Lilly is expected to begin a Phase 1 dose escalation study with FHD-909, a selective BRM inhibitor, later in 2024.
• The company believes its current pipeline has the potential to help more than 500,000 cancer patients.
• Foghorn anticipates filing six new Investigational New Drug Applications (INDs) over the next four years.
• A strategic collaboration with Lilly includes co-development and co-commercialization of the selective BRM oncology program and an additional undisclosed oncology target.
• Lilly made an upfront payment of $300 million and an $80 million equity investment in Foghorn.
• Foghorn is eligible to receive a share of U.S. profits for co-commercialized products and tiered royalties on ex-U.S. sales.
• The company reported a net loss of $98.4 million for the year ended December 31, 2023, and has an accumulated deficit of $471.6 million.
• As of December 31, 2023, Foghorn had cash, cash equivalents, and marketable securities of $234.1 million.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive aspects such as the strategic collaboration with Lilly and the potential of the company's technology, the significant losses, reliance on future funding, and the risks associated with clinical development temper the overall sentiment. The clinical hold and program termination also contribute to a neutral to slightly negative outlook.

Positives

• The strategic collaboration with Lilly validates Foghorn's science and highlights the importance of the targets they are tackling.
• The company has a unique ability to study the chromatin regulatory system at scale, in context, and in an integrated way.
• Foghorn has a diverse pipeline of product candidates targeting genetically determined dependencies within the chromatin regulatory system.
• The company has a strong leadership team with deep scientific, clinical, manufacturing, business, and leadership expertise.
• The company has a modality agnostic approach to drugging targets, including protein degraders, allosteric enzymatic inhibitors, and transcription factor disruptors.
• The company has a biology first approach, focusing on the underlying genetics and biology of a disease relevant target.
• The company has a proprietary library of linkers and E3 ligase binders for heterobifunctional degrader development.
• The company has a proprietary screening strategy for novel non-cereblon based molecular glue discovery.
• The company has developed capabilities with long-acting formulation of protein degraders.
• The company has demonstrated that selective degradation of either CBP alone or EP300 alone in animal models does not cause thrombocytopenia.

Negatives

• The company has incurred significant losses since inception and expects to incur losses for the foreseeable future.
• The company has a limited operating history and no products approved for commercial sale.
• The company is heavily dependent on the success of its product candidates, which are in preclinical and Phase 1 clinical development.
• Clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of product candidates.
• The company may not be able to file INDs or IND amendments on expected timelines.
• The company's lead product candidate utilizes a novel mechanism of action, which may result in greater research and development expenses and regulatory issues.
• There is substantial competition in the field, which may result in others developing or commercializing products before Foghorn.
• The company is highly dependent on key personnel and may not be successful in attracting and retaining qualified personnel.
• The company may be unable to adequately protect its proprietary technology and platform or obtain and maintain patent protection.
• Unfavorable global macroeconomic conditions, geopolitical trends, and armed conflict could adversely affect the company's business.

Risks

• The company has a limited operating history and has no products approved for commercial sale, which may make it difficult to evaluate its current business and predict future success.
• The company has incurred significant losses since inception and may never achieve or maintain profitability.
• The company will need substantial additional funding and may be forced to delay, reduce, or eliminate research and development programs if unable to raise capital.
• The company is heavily dependent on the success of its product candidates, which are in preclinical and Phase 1 clinical development.
• Clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of product candidates.
• The company may not be able to file INDs or IND amendments to commence clinical trials on expected timelines.
• The company's lead product candidate utilizes a novel mechanism of action, which may result in greater research and development expenses and regulatory issues.
• There is substantial competition in the field, which may result in others developing or commercializing products before Foghorn.
• The company is highly dependent on key personnel and may not be successful in attracting and retaining qualified personnel.
• The company may be unable to adequately protect its proprietary technology and platform or obtain and maintain patent protection.
• Unfavorable global macroeconomic conditions, geopolitical trends, and armed conflict could adversely affect the company's business.
• The company may not be able to exert unilateral control over the development of product candidates when part of a collaboration.

Future Outlook

The company expects to continue to incur significant expenses and increasing operating losses for the foreseeable future. They anticipate filing six new INDs over the next four years and are committed to applying their Gene Traffic Control platform to additional therapeutic areas over time.

Management Comments

• We believe Foghorn has the potential to be a major biopharmaceutical company with our current pipeline addressing more than 20 tumor types impacting more than 500,000 new patients annually.
• We believe that we have the potential to file six new Investigational New Drug Applications ( INDs) over the next four years.
• We believe this strategic collaboration confirms the rigor of our science, highlights the importance of the targets we are tackling and underscores the relevance of the biology on which we are focused.

Industry Context

The document highlights the competitive landscape in the biotechnology and pharmaceutical industries, noting that many competitors have greater resources and expertise. It also mentions the increasing interest in therapies targeting broad genetic expression mechanisms, including the chromatin regulatory system, and the development of protein degradation approaches by other companies.

Comparison to Industry Standards

• The document mentions several competitors in the targeted therapy space, including Prelude Therapeutics Incorporated, Plexium, Inc., Amgen Inc., Abbvie Inc., Genentech, Inc., and SK Life Science, Inc.
• It also notes competition from companies developing protein degradation approaches, such as Arvinas, Inc., Kymera Therapeutics, Inc., Nurix Therapeutics, Inc., and C4 Therapeutics, Inc.
• The document highlights that Foghorn is the only company with the ability to study the chromatin regulatory system at scale, in context, and in an integrated way, which is a key differentiator.
• The document notes that mutations in the chromatin regulatory system are found in over 50% of all cancers, potentially impacting over 2.5 million cancer patients across the United States, Europe and Japan, indicating a large potential market for Foghorn's therapies.
• The document also mentions that BRG1 mutations are found in 10% of NSCLC tumors, highlighting the importance of developing novel therapeutics that address this unmet need.

Related Party Transactions

• The company has a consulting agreement with a scientific founder who is also a shareholder.
• The company has a strategic collaboration with Lilly, who is also a 5% or greater shareholder.

Stakeholder Impact

• Shareholders face risks related to the company's financial performance, clinical trial outcomes, and competition.
• Employees are subject to the company's success in attracting and retaining qualified personnel.
• Patients may benefit from the development of new therapies targeting the chromatin regulatory system.
• The company's suppliers and partners are subject to the company's ability to fund its operations and meet its contractual obligations.

Next Steps

• Advance FHD-286 through clinical development in patients with select solid tumors and hematological cancers.
• Lilly will begin a Phase 1 dose escalation study with FHD-909 later this year.
• Expand the precision oncology pipeline by developing proprietary enzymatic inhibitors, degraders, and disruptors.
• Harness the platform to develop novel product candidates to address therapeutic areas beyond oncology.
• Continue to enhance the platform to extend the company's leading position in developing novel therapeutics targeting the chromatin regulatory system.
• Selectively enter into additional strategic partnerships to maximize the potential of the pipeline and platform.

Key Dates

Keywords

chromatin regulatory system, precision therapeutics, oncology, FHD-286, FHD-909, BRM, BRG1, AML, protein degraders, enzyme inhibitors, Lilly, Gene Traffic Control platform, clinical trials, IND, biotechnology